文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

法国扩大标准供者低温保存与肾移植延迟移植功能的多中心随机对照试验(HYPOREME)

Hypothermia for expanded criteria organ donors in kidney transplantation in France (HYPOREME): a multicentre, randomised controlled trial.
PubMed 文献 · Lancet Respir Med · 2024-06-11
一句话结论扩大标准供者低温(34-35°C)未降低肾移植延迟移植功能(16% vs 21%,OR 0.71,p=0.14),但1年时受者血肌酐更低、肌酐清除率更高。

HYPOREME试验在法国53个ICU和移植中心纳入扩大标准供者(>60岁,或50-59岁且至少两项危险因素:高血压史、肌酐>132 μmol/L、脑血管原因死亡)及相应肾移植受者,随机分为供者低温(34-35°C)或常温(36.5-37.5°C),常规使用机器灌注。主要终点延迟移植功能(移植后7天内需肾脏替代治疗)在低温组40/251(16%)vs 常温组58/275(21%),OR 0.71(95%CI 0.44-1.13),p=0.14,绝对差-5.2%(95%CI -11.8至1.5)。1年时低温组平均肌酐152.4 μmol/L vs 169.7 μmol/L(p=0.0351),平均肌酐清除率42.3 vs 40.5 mL/min/1.73m2(p=0.0414)。作者结论:常规机器灌注下供者低温未降低延迟移植功能频率,但与1年时更低的血肌酐和更高的肌酐清除率相关。

要点

  • 扩大标准供者低温(34-35°C)与常温(36.5-37.5°C)相比,肾移植延迟移植功能(移植后7天内肾脏替代治疗)发生率16%(40/251)vs 21%(58/275),OR 0.71(95%CI 0.44-1.13),p=0.14,未达统计学显著。
  • 低温组供者最高平均动脉压高于常温组(115 mmHg [SD 22] vs 108 mmHg [20],p=0.001)。
  • 移植后1年,低温组受者平均血肌酐低于常温组(152.4 μmol/L [SD 59.1] vs 169.7 μmol/L [51.4],p=0.0351)。
  • 移植后1年,低温组受者平均肌酐清除率高于常温组(42.3 mL/min/1.73 m2 [SD 15.8] vs 40.5 mL/min/1.73 m2 [17.9],p=0.0414)。
  • 其他次要终点(供者器官获取与移植数量、肾功能、体温、总输液量、血压、血管加压药和正性肌力药需求、不良事件;受者住院时长、移植肾功能与第7天/28天/3个月/1年生存状态、感染/心血管事件/手术并发症)两组间无显著差异。

适用人群与场景

  • 纳入扩大标准供者:年龄>60岁,或年龄50-59岁且至少具备两项其他危险因素(高血压史、肌酐>132 μmol/L、脑血管原因死亡)。
  • 供者死亡基于神经学标准诊断,符合法国法律。
  • 纳入相应肾移植受者;mITT分析纳入至少接受一个扩大标准供者肾脏的所有受者,但排除受监护的受者。
  • 研究在法国53个ICU和移植中心进行。

诊断标准与关键阈值

  • 扩大标准供者定义:年龄>60岁,或年龄50-59岁且至少两项其他危险因素(高血压史、肌酐>132 μmol/L、脑血管原因死亡)。
  • 延迟移植功能定义:移植后7天内需要肾脏替代治疗。

处置流程与药物剂量

  • 供者随机分配至低温(34-35°C)或常温(36.5-37.5°C)。
  • 常规使用机器灌注保存器官。

研究设计与关键结果

  • 多中心、随机、对照、平行组试验,在法国53个ICU和移植中心进行;2017年11月9日至2021年3月3日随机分配365名供者,其中298名供者(151名[51%]男性,147名[49%]女性)提供肾脏给526名受者(323名[61%]男性,203名[39%]女性)。
  • mITT分析纳入低温组251名受者和常温组275名受者。
  • 主要终点延迟移植功能:低温组40/251(16%)vs 常温组58/275(21%),OR 0.71(95%CI 0.44-1.13),p=0.14,绝对差-5.2%(95%CI -11.8至1.5)。
  • 供者最高平均动脉压:低温组115 mmHg(SD 22)vs 常温组108 mmHg(SD 20),p=0.001。
  • 移植后1年平均血肌酐:低温组152.4 μmol/L(SD 59.1)vs 常温组169.7 μmol/L(SD 51.4),p=0.0351。
  • 移植后1年平均肌酐清除率:低温组42.3 mL/min/1.73 m2(SD 15.8)vs 常温组40.5 mL/min/1.73 m2(SD 17.9),p=0.0414。
  • 其他次要终点两组间均无显著差异。

证据类型、等级与局限

  • 证据类型:多中心、随机、对照、平行组试验。
  • 结果评估者设盲;研究者设盲不可行。
  • 局限:研究者设盲不可行;原文未报告其他局限性。

对床旁实践的改变

  • 作者认为:在器官常规使用机器灌注保存的扩大标准供者中,低温未降低延迟移植功能频率;但低温与移植后1年更低血清肌酐浓度和更高肌酐清除率相关。
  • 原文未据此给出推荐。

指南或共识出处

  • HYPOREME试验,注册号NCT03098706;资助:法国卫生部与法国重症医学会。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Expanded criteria donors help to increase graft availability, but provide organs with an increased risk of delayed graft function. We aimed to investigate whether donor hypothermia decreases the risk of delayed graft function compared with normothermia.

METHODS: We did this multicentre, randomised, controlled, parallel-arm trial at 53 intensive care units and transplant centres in France. We included expanded criteria donors in whom death was diagnosed based on neurological criteria, in compliance with French law, and the recipients of their kidney grafts. Eligible expanded criteria donors were older than 60 years or were aged 50-59 years and had at least two other risk factors (history of hypertension, creatinine >132 μmol/L, or cerebrovascular cause of death). Donors were randomly assigned to hypothermia (34-35°C) or normothermia (36·5-37·5°C). Machine perfusion was used routinely. Randomisation was done using a computer-generated, interactive, web-response system, in permuted blocks (block size six), stratified by centre. Outcome assessors were masked; investigator masking was not feasible. The primary outcome was the proportion of kidney recipients with delayed graft function, defined as renal replacement therapy within 7 days after transplantation, assessed in the modified intention-to-treat (mITT) population, which included all recipients who received at least one kidney from an expanded criteria donor, with the exception of those under guardianship. Secondary outcomes in expanded criteria donors were the number of organs recovered and transplanted, kidney function, body temperature, total volume of fluids administered, blood pressure and need for vasopressors and inotropes, and adverse events (cardiovascular events, metabolic disturbances, and coagulation disorders). Secondary outcomes in kidney recipients were duration of hospital stay, kidney graft function and vital status at day 7, day 28, 3 months, and 1 year after transplantation, and adverse events (infections, cardiovascular events, and surgical complications). Secondary outcomes were assessed in the mITT population. The trial was registered at ClinicalTrials.gov, NCT03098706.

FINDINGS: Between Nov 9, 2017, and March 3, 2021, 365 donors were randomly assigned, of whom 298 (151 [51%] male, 147 [49%] female) provided kidneys to 526 recipients (323 [61%] male, 203 [39%] female). 251 recipients in the hypothermia group and 275 recipients in the normothermia group were included in the analysis. Graft function was delayed in 40 (16%) of 251 recipients in the hypothermia group and 58 (21%) of 275 recipients in the normothermia group (odds ratio 0·71 [95% CI 0·44-1·13]; p=0·14; absolute difference -5·2% [95% CI 11·8-1·5]). Compared with donors in the normothermia group, donors in the hypothermia group had higher highest mean arterial pressure (115 mm Hg [SD 22] vs 108 mm Hg [20]; p=0·001). 1 year after transplantation, recipients in the hypothermia group had a lower mean creatinine concentration (152·4 μmol/L [SD 59·1] vs 169·7 μmol/L [51·4]; p=0·0351) and a higher mean creatinine clearance (42·3 mL/min/1·73 m2 [15·8] vs 40·5 mL/min/1·73 m2 [17·9]; p=0·0414) than those in the normothermia group. No significant differences between groups were identified for any other secondary outcomes.

INTERPRETATION: Hypothermia in expanded criteria donors whose organs were routinely stored using machine perfusion did not decrease the frequency of delayed kidney graft function. However, hypothermia was associated with a lower serum creatinine concentration and a higher creatinine clearance 1 year after transplantation.

FUNDING: French Ministry of Health and French Intensive Care Society.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Hypothermia for expanded criteria organ donors in kidney transplantation in France (HYPOREME): a multicentre, randomised controlled trial. Lancet Respir Med. 2024. PMID: 38876137. doi:10.1016/S2213-2600(24)00117-6

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。